eClinicalOS Welcomes Watson!
The hallways at eClinicalOS headquarters are positively buzzing this week! Why the fuss? Well, we just got some VERY exciting news about our future. (We think you’ll find it to be great news, too!)
As you may have heard, Merge Healthcare, the parent company of eClinicalOS, announced last week that we have entered into a definitive agreement under which IBM plans to acquire Merge Healthcare. After closing, Merge Healthcare (and the Merge eClinical division) will become part of the IBM Watson Health unit.
Joining together our strengths as a leader in clinical trial management software with IBM’s powerful Watson Health Cloud cognitive and analytic capabilities will enable us to exponentially expand the reach and effectiveness of our solutions.
We foresee a future in which healthcare and clinical research organizations can use the Watson Health Cloud to glean new and exciting insights from a multitude of data sources. Additionally, we hope to gain huge benefits from the ample resources IBM can offer to support the continued growth and development of our business.
Reaction from Merge Leadership
Justin Dearborn, chief executive officer of Merge, is thrilled by this development. “Merge is widely recognized for delivering market leading imaging workflow and electronic data capture solutions,” he said. “Today’s announcement is an exciting step forward for our employees and clients. Becoming a part of IBM will allow us to expand our global scale and deliver added value and insight to our clients through Watson’s advanced analytic and cognitive computing capabilities.”
Zaher El-Assi, president of the eClinical division, also had positive things to say about the IBM-Merge agreement. "The application of advanced IT to the drug and device development process continues to be the most significant trend in clinical research today," he said. "We believe the ability to tap IBM's global data management expertise and the capabilities of Watson, the world's most powerful supercomputer, will help eClinicalOS clients – and our team – advance clinical research and improve the human condition in truly historic ways.”
No changes in day-to-day business expected
Until the close of this acquisition, we want to assure you that nothing is changing for you, our customers and users. After close of this transaction, Merge products, including eClinicalOS and CTMS for Investigators, will only become better – and you will benefit from continued innovation to support your clinical research needs.
In short, this is our promise: You can continue to expect the same level of service that you have come to rely on from eClinicalOS.
Announcement only the first step
While we are very excited about the news, this is just the first step in the process. This transaction is subject to regulatory review, Merge shareholder approval and satisfaction of customary closing conditions and is expected to close later this year. Until the transaction closes, Merge will remain an independent company, and it is business as usual. We remain focused, as we always have, on execution and results, and will continue to deliver the innovation and support that you have come to expect from us.
We’ll stay in touch as future developments take place. If you have any questions about this announcement, please don’t hesitate to reach out.
As always, thank you for your continued business and ongoing support. We're proud to say that we have the very best customers and users in the industry, and that is one thing that will never change.
You can read more abou the Merge Healthcare and IBM acquisition here.